Citation: 陈甜甜, 时国朝. 恒定型自然杀伤细胞在哮喘中的研究进展. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(5): 524-528. doi: 10.7507/1671-6205.2015130 Copy
1. | Akbari O, Faul JL, Hoyte EG, et al. CD4+ invariant T-cell receptor+ natural killer T cells in bronchial asthma. N Engl J Med, 2006, 354:1117-1129. |
2. | Seddon Y, Thomas, Yung H, et al. NKT cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. J Allergy Clin Immunol, 2010, 125:980-984. |
3. | Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med, 2003, 9:582-588. |
4. | Hachem P, Lisbonne M, Michel ML, et al.α-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice:role of IFN-γ. Eur J Immunol, 2005, 35:2793-2802. |
5. | Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol, 2002, 2:5575-5568. |
6. | Bienemann K, Iouannidou K, Schoenberg K, et al. iNKT cell frequency in peripheral blood of Caucasian children and adolescent:the absolute iNKT cell count is stable from birth to adulthood. Scand J Immunol, 2010, 74:406-411. |
7. | Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology, 2007, 122:1-14. |
8. | Lisbonne M, Leite-de-Moraes MC. Invariant Va14 NKT lymphocytes:a double-edged immuno-regulatory T cell population. Eur Cytokine Netw, 2003, 14:4-14. |
9. | Godfrey DI, Kronenberg M. Going both ways:immune regulation via CD1d-dependent NKT cells. J Clin Invest, 2004, 114:1379-1388. |
10. | Kronenberg M. Toward an understanding of NKT cell biology:progress and paradoxes. Annu Rev Immunol, 2005, 23:877-900. |
11. | Kawano T, Cui J, Koezuka, Y, et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science, 1997, 278:1626-1629. |
12. | Mendiratta SK, Martin WD, Hong S, et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity, 1997, 6:469-477. |
13. | Cui JQ, Watanabe N, Kawano T, et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J Exp Med, 1999, 190:783-792. |
14. | Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells:bridging innate and adaptive immunity. Cell Tissue Res, 2010, 343:43-55. |
15. | Thomas SY, Chyung YH, Luster AD. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. J Allergy Clin Immunol, 2010, 125:980-984. |
16. | Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol, 2007, 25:297-336. |
17. | Lee YJ, Holzapfel KL, Zhu J, et al. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of INKT cells. Nat Immunol, 2013, 14:1146-1154. |
18. | Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions. Nat Rev Immunol, 2013, 13:101-117. |
19. | Lantz O, Bendelac A. An invariant T cell receptorαchain is used by a unique subset of major histocompatibility complex classⅠ-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med, 1994, 180:1097-1106. |
20. | Chan SH, Cosgrove D, Waltzinger C, et al. Another view of the selective model of thymocyte selection. Cell, 1993, 73:225-236. |
21. | Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol, 2003, 21:483-513. |
22. | Scneuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8(9):e76682. |
23. | Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1d lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature, 2007, 448:44-49. |
24. | Scott-Browne JP, Matsuda JL, Mallevaey T, et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol, 2007, 8:1105-1113. |
25. | Mallevaey T, Scott-Browne JP, Matsuda JL, et al. T cell receptor CDR2βand CDR3βloops collaborate functionally to shape the iNKT cell repertoire. Immunity, 2009, 31:60-71. |
26. | Pellicci DG, Patel O, Kjer-Nielsen L, et al. Differential recognition of CD1d-α-galactosyl ceramide by the Vβ8.2 and Vβ7 semi-invariant NKT T cell receptors. Immunity, 2009, 31:47-59. |
27. | Akbari O, Stock P, Meyer EH, et al. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol, 2008, 180:5448-5456. |
28. | Burdin N, Brossay L, Koezuka Y, et al. Selective ability of mouse CD1 to present glycolipids:α-galactosylceramide specifically stimulates Vα14+NK T lymphocytes. J Immunol, 1998, 161:3271-3281. |
29. | Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol, 2010, 22:79-86. |
30. | Centers for Disease Control and Prevention (CDC). Forecasted state-specific estimates of self-reported asthma prevalence-United States, 1998. Morb Mortal Wkly Rep, 1998, 47:1022-1025. |
31. | Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol, 1999, 17:255-281. |
32. | Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998, 282:2261-2263. |
33. | Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13:central mediator of allergic asthma. Science, 1998, 282:2258-2261. |
34. | Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med, 1992, 326:298-304. |
35. | Matsuda H, Suda T, Sato J, et al.α-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am J Respir Cell Mol Biol, 2005, 33:22-31. |
36. | Lombardi V, Stock P, Singh AK, et al. a CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol, 2010, 184:2107-2115. |
37. | Li L, Xia YY, Nguyen A, et al. Effects of Th2 cytokines on chemokine expression in the lung:IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol, 1999, 162:2477-2487. |
38. | Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol, 2001, 24:755-761. |
39. | Chuang YH, Wang TC, Jen HY, et al.α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells. J Immunol, 2011, 186:4687-4692. |
40. | Lisbonne M, Diem S, de Castro Keller A, et al. Cutting edge:invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol, 2003, 171:1637-1641. |
41. | Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol, 2010, 3:81-91. |
42. | Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol, 2006, 24:147-174. |
43. | Koh YI, Shim JU. Association between sputum natural killer T cells and eosinophilic airway inflammation in human asthma. Int Arch Allergy Immunol, 2010, 153:239-248. |
44. | Shim JU, Koh YI. Increased Th2-like invariant natural killer T cells in peripheral blood from patients with asthma. Allergy Asthma Immunol Res, 2014, 6:444-448. |
45. | Carpio-Pedroza JC, Vaughan G, del Rio-Navarro BE, et al. Participation of CD161(+) and invariant natural killer T cells in pediatric asthma exacerbations. Allergy Asthma Proc, 2013, 34:84-92. |
46. | Morishima Y, Ishii Y, Kimura T, et al. Suppression of eosinophilic airway inflammation by treatment withα-galactosylceramide. Eur J Immunol, 2005, 35:2803-2814. |
47. | Grela F, Aumeunier A, Bardel E, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-γ. J Immunol, 2011, 186:284-290. |
48. | Scheuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8:e76692. |
- 1. Akbari O, Faul JL, Hoyte EG, et al. CD4+ invariant T-cell receptor+ natural killer T cells in bronchial asthma. N Engl J Med, 2006, 354:1117-1129.
- 2. Seddon Y, Thomas, Yung H, et al. NKT cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. J Allergy Clin Immunol, 2010, 125:980-984.
- 3. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med, 2003, 9:582-588.
- 4. Hachem P, Lisbonne M, Michel ML, et al.α-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice:role of IFN-γ. Eur J Immunol, 2005, 35:2793-2802.
- 5. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol, 2002, 2:5575-5568.
- 6. Bienemann K, Iouannidou K, Schoenberg K, et al. iNKT cell frequency in peripheral blood of Caucasian children and adolescent:the absolute iNKT cell count is stable from birth to adulthood. Scand J Immunol, 2010, 74:406-411.
- 7. Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology, 2007, 122:1-14.
- 8. Lisbonne M, Leite-de-Moraes MC. Invariant Va14 NKT lymphocytes:a double-edged immuno-regulatory T cell population. Eur Cytokine Netw, 2003, 14:4-14.
- 9. Godfrey DI, Kronenberg M. Going both ways:immune regulation via CD1d-dependent NKT cells. J Clin Invest, 2004, 114:1379-1388.
- 10. Kronenberg M. Toward an understanding of NKT cell biology:progress and paradoxes. Annu Rev Immunol, 2005, 23:877-900.
- 11. Kawano T, Cui J, Koezuka, Y, et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science, 1997, 278:1626-1629.
- 12. Mendiratta SK, Martin WD, Hong S, et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity, 1997, 6:469-477.
- 13. Cui JQ, Watanabe N, Kawano T, et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J Exp Med, 1999, 190:783-792.
- 14. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells:bridging innate and adaptive immunity. Cell Tissue Res, 2010, 343:43-55.
- 15. Thomas SY, Chyung YH, Luster AD. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. J Allergy Clin Immunol, 2010, 125:980-984.
- 16. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol, 2007, 25:297-336.
- 17. Lee YJ, Holzapfel KL, Zhu J, et al. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of INKT cells. Nat Immunol, 2013, 14:1146-1154.
- 18. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions. Nat Rev Immunol, 2013, 13:101-117.
- 19. Lantz O, Bendelac A. An invariant T cell receptorαchain is used by a unique subset of major histocompatibility complex classⅠ-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med, 1994, 180:1097-1106.
- 20. Chan SH, Cosgrove D, Waltzinger C, et al. Another view of the selective model of thymocyte selection. Cell, 1993, 73:225-236.
- 21. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol, 2003, 21:483-513.
- 22. Scneuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8(9):e76682.
- 23. Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1d lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature, 2007, 448:44-49.
- 24. Scott-Browne JP, Matsuda JL, Mallevaey T, et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol, 2007, 8:1105-1113.
- 25. Mallevaey T, Scott-Browne JP, Matsuda JL, et al. T cell receptor CDR2βand CDR3βloops collaborate functionally to shape the iNKT cell repertoire. Immunity, 2009, 31:60-71.
- 26. Pellicci DG, Patel O, Kjer-Nielsen L, et al. Differential recognition of CD1d-α-galactosyl ceramide by the Vβ8.2 and Vβ7 semi-invariant NKT T cell receptors. Immunity, 2009, 31:47-59.
- 27. Akbari O, Stock P, Meyer EH, et al. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol, 2008, 180:5448-5456.
- 28. Burdin N, Brossay L, Koezuka Y, et al. Selective ability of mouse CD1 to present glycolipids:α-galactosylceramide specifically stimulates Vα14+NK T lymphocytes. J Immunol, 1998, 161:3271-3281.
- 29. Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol, 2010, 22:79-86.
- 30. Centers for Disease Control and Prevention (CDC). Forecasted state-specific estimates of self-reported asthma prevalence-United States, 1998. Morb Mortal Wkly Rep, 1998, 47:1022-1025.
- 31. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol, 1999, 17:255-281.
- 32. Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998, 282:2261-2263.
- 33. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13:central mediator of allergic asthma. Science, 1998, 282:2258-2261.
- 34. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med, 1992, 326:298-304.
- 35. Matsuda H, Suda T, Sato J, et al.α-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am J Respir Cell Mol Biol, 2005, 33:22-31.
- 36. Lombardi V, Stock P, Singh AK, et al. a CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol, 2010, 184:2107-2115.
- 37. Li L, Xia YY, Nguyen A, et al. Effects of Th2 cytokines on chemokine expression in the lung:IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol, 1999, 162:2477-2487.
- 38. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol, 2001, 24:755-761.
- 39. Chuang YH, Wang TC, Jen HY, et al.α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells. J Immunol, 2011, 186:4687-4692.
- 40. Lisbonne M, Diem S, de Castro Keller A, et al. Cutting edge:invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol, 2003, 171:1637-1641.
- 41. Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol, 2010, 3:81-91.
- 42. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol, 2006, 24:147-174.
- 43. Koh YI, Shim JU. Association between sputum natural killer T cells and eosinophilic airway inflammation in human asthma. Int Arch Allergy Immunol, 2010, 153:239-248.
- 44. Shim JU, Koh YI. Increased Th2-like invariant natural killer T cells in peripheral blood from patients with asthma. Allergy Asthma Immunol Res, 2014, 6:444-448.
- 45. Carpio-Pedroza JC, Vaughan G, del Rio-Navarro BE, et al. Participation of CD161(+) and invariant natural killer T cells in pediatric asthma exacerbations. Allergy Asthma Proc, 2013, 34:84-92.
- 46. Morishima Y, Ishii Y, Kimura T, et al. Suppression of eosinophilic airway inflammation by treatment withα-galactosylceramide. Eur J Immunol, 2005, 35:2803-2814.
- 47. Grela F, Aumeunier A, Bardel E, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-γ. J Immunol, 2011, 186:284-290.
- 48. Scheuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8:e76692.
-
Previous Article
Epac在哮喘气道重塑中的作用及机制